Pay in 4 interest-free payments of $6.00 Learn more
Ships within 48 hours · Estimated delivery Sep 27 - Oct 2
Soc., Trans
Liu Q, Zhu J, Kong B, Shuai W, Huang H
Such effects are consistent with their established reduction in atherosclerotic cardiovascular events and may be particularly relevant in patients with obesity, insulin resistance, or HFpEF phenotypes, and taken together, these mechanistic differences provide a biologically plausible rationale for combination therapy: SGLT2 inhibitors primarily target HF-related hemodynamic and cardiorenal pathways, whereas GLP-1 receptor agonists may further improve metabolic and vascular risk
Decreased in vivo oxidative stress and decreased platelet activation following Metformin treatment in newly diagnosed type 2 diabetic subjects
